Paul J Maddon

发表

Evaluating the Immunogenicity of a Disulfide-Stabilized, Cleaved, Trimeric Form of the Envelope Glycoprotein Complex of Human Immunodeficiency Virus Type 1

William C. Olson, Elizabeth Michael, N. Schülke, 2005, Journal of Virology.

Oligomeric and Conformational Properties of a Proteolytically Mature, Disulfide-Stabilized Human Immunodeficiency Virus Type 1 gp140 Envelope Glycoprotein

Min Lu, Paul W. H. I. Parren, Kenneth H. Roux, 2002, Journal of Virology.

The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy

William C. Olson, N. Schülke, Paul J Maddon, 2003, Proceedings of the National Academy of Sciences of the United States of America.

Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1.

J. Binley, John P. Moore, T. Parsons, 2009, Vaccine.

A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120.

John P. Moore, R. Desrosiers, P. Klasse, 2007, Virology.

Novel Small-Molecule Inhibitors of Hepatitis C Virus Entry Block Viral Spread and Promote Viral Clearance in Cell Culture

Paul J Maddon, W. Olson, Y. Rotshteyn, 2012, PloS one.

Immunotoxines anti-cd19

Paul J Maddon, W. Olson, D. Ma, 2002 .

Potent, Broad-Spectrum Inhibition of Human Immunodeficiency Virus Type 1 by the CCR5 Monoclonal Antibody PRO 140

A. Trkola, John P. Moore, T. Ketas, 2001, Journal of Virology.

Anti – HIV-1 Activity of Weekly or Biweekly Treatment with Subcutaneous PRO 140 , a CCR 5 Monoclonal Antibody

N. Stambler, M. Saag, A. Marozsan, 2010 .

Stabilization of the Soluble, Cleaved, Trimeric Form of the Envelope Glycoprotein Complex of Human Immunodeficiency Virus Type 1

John P. Moore, B. Berkhout, R. Sanders, 2002, Journal of Virology.

Construction and characterization of soluble, cleaved, and stabilized trimeric Env proteins based on HIV type 1 Env subtype A.

John P. Moore, J. Overbaugh, S. Beddows, 2006, AIDS research and human retroviruses.

L-SIGN (CD 209L) is a liver-specific capture receptor for hepatitis C virus

Paul J Maddon, W. Olson, T. Dragic, 2003, Proceedings of the National Academy of Sciences of the United States of America.

Amino-Terminal Substitutions in the CCR5 Coreceptor Impair gp120 Binding and Human Immunodeficiency Virus Type 1 Entry

William C. Olson, Thomas P. Sakmar, A. Trkola, 1998, Journal of Virology.

by Monoclonal Antibodies to CCR5 gp120 Binding, and CC-Chemokine Activity Immunodeficiency Virus Type 1 Fusion, Differential Inhibition of Human

John P. Moore, G. Rabut, Paul J Maddon, 2012 .

Differential Inhibition of Human Immunodeficiency Virus Type 1 Fusion, gp120 Binding, and CC-Chemokine Activity by Monoclonal Antibodies to CCR5

William C. Olson, Yong Guo, Jeremy P. Segal, 1999, Journal of Virology.

CD4-Immunoglobulin G2 Protects Hu-PBL-SCID Mice against Challenge by Primary Human Immunodeficiency Virus Type 1 Isolates

R. Koup, Paul J Maddon, W. Olson, 1998, Journal of Virology.

Potent Antitumor Activity of an Auristatin-Conjugated, Fully Human Monoclonal Antibody to Prostate-Specific Membrane Antigen

Paul J Maddon, W. Olson, P. Senter, 2006, Clinical Cancer Research.

Treatment of Advanced Human Immunodeficiency Virus Type 1 Disease with the Viral Entry Inhibitor PRO 542

John P. Moore, C. Petropoulos, T. Ketas, 2004, Antimicrobial Agents and Chemotherapy.

L-SIGN (CD209L) isoforms differently mediate trans-infection of hepatoma cells by hepatitis C virus pseudoparticles.

E. Falkowska, Paul J Maddon, W. Olson, 2006, The Journal of general virology.

A Novel Alphavirus Vaccine Encoding Prostate-Specific Membrane Antigen Elicits Potent Cellular and Humoral Immune Responses

Maureen F. Maughan, Paul J Maddon, W. Olson, 2007, Clinical Cancer Research.

A Recombinant Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Complex Stabilized by an Intermolecular Disulfide Bond between the gp120 and gp41 Subunits Is an Antigenic Mimic of the Trimeric Virion-Associated Structure

J. Binley, John P. Moore, B. Clas, 2000, Journal of Virology.

Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody.

N. Stambler, M. Saag, A. Marozsan, 2010, The Journal of infectious diseases.

Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults.

R. Redfield, C. Fichtenbaum, M. Saag, 2008, The Journal of infectious diseases.

Potent AntitumorActivity of an Auristatin-Conjugated , Fully Human Monoclonal Antibody to Prostate-SpecificMembrane Antigen

Paul J Maddon, W. Olson, P. Senter, 2006 .

Phase 2a Study of the CCR5 Monoclonal Antibody PRO 140 Administered Intravenously to HIV-Infected Adults

C. Fichtenbaum, N. Stambler, M. Saag, 2010, Antimicrobial Agents and Chemotherapy.

Potent Antiviral Synergy between Monoclonal Antibody and Small-Molecule CCR5 Inhibitors of Human Immunodeficiency Virus Type 1

M. Franti, Paul J Maddon, W. Olson, 2006, Antimicrobial Agents and Chemotherapy.

Protection against Clostridium difficile infection with broadly neutralizing antitoxin monoclonal antibodies.

B. Kennedy, A. Marozsan, Paul J Maddon, 2012, The Journal of infectious diseases.

Anticorps contre le PSMA

N. Schülke, Paul J Maddon, W. Olson, 2002 .

Purified, proteolytically mature HIV type 1 SOSIP gp140 envelope trimers.

John P. Moore, K. Roux, S. Beddows, 2007, AIDS research and human retroviruses.

PRO 140, a monoclonal antibody targeting CCR5, as a long-acting, single-agent maintenance therapy for HIV-1 infection

S. Badri, Paul J Maddon, D. Burger, 2018, HIV clinical trials.